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Abstract
Background: The new 2010 World Health Organization (WHO) HIV treatment guidelines recommend earlier antiretroviral
therapy (ART) initiation (CD4,350 cells/ml instead of CD4,200 cells/ml), multiple sequential ART regimens, and replacement
of first-line stavudine with tenofovir. This paper considers what to do first in resource-limited settings where immediate
implementation of all of the WHO recommendations is not feasible.
Methods and Findings: We use a mathematical model and local input data to project clinical and economic outcomes in a
South African HIV-infected cohort (mean age=32.8 y, mean CD4=375/ml). For the reference strategy, we assume that all
patients initiate stavudine-based ART with WHO stage III/IV disease and receive one line of ART (stavudine/WHO/one-line).
We rank—in survival, cost-effectiveness, and equity terms—all 12 possible combinations of the following: (1) stavudine
replacement with tenofovir, (2) ART initiation (by WHO stage, CD4,200 cells/ml, or CD4,350 cells/ml), and (3) one or two
regimens, or lines, of available ART. Projected life expectancy for the reference strategy is 99.0 mo. Considering each of the
guideline components separately, 5-y survival is maximized with ART initiation at CD4,350 cells/ml (stavudine/,350/ml/
one-line, 87% survival) compared with stavudine/WHO/two-lines (66%) and tenofovir/WHO/one-line (66%). The greatest life
expectancies are achieved via the following stepwise programmatic additions: stavudine/,350/ml/one-line (124.3 mo),
stavudine/,350/ml/two-lines (177.6 mo), and tenofovir/,350/ml/two-lines (193.6 mo). Three program combinations are
economically efficient: stavudine/,350/ml/one-line (cost-effectiveness ratio, US$610/years of life saved [YLS]), tenofovir/
,350/ml/one-line (US$1,140/YLS), and tenofovir/,350/ml/two-lines (US$2,370/YLS).
Conclusions: In settings where immediate implementation of all of the new WHO treatment guidelines is not feasible, ART
initiation at CD4,350 cells/ml provides the greatest short- and long-term survival advantage and is highly cost-effective.
Please see later in the article for the Editors’ Summary.
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The 2006 World Health Organization (WHO) guidelines on
antiretroviral therapy (ART) established a worldwide standard of
care for patients with HIV infection [1]. Since this publication,
new evidence has emerged on how to treat patients infected with
HIV, and this evidence formed the basis for the WHO 2010 ART
guidelines update [2]. These revisions aim to better align global
standards with those already adopted in well-resourced countries
[3,4]. Specifically, revised guidelines recommend an increased
number of sequential ART regimens, routinely available CD4
count monitoring, earlier ART initiation thresholds
(CD4,350 cells/ml versus CD4,200 cells/ml), and replacement
of stavudine with the less-toxic drug tenofovir.
As WHO expands treatment recommendations, many countries
in resource-limited settings still struggle to implement 2006
guidelines [5]. In Malawi, for example, most HIV disease is
monitored clinically; CD4 count monitoring is limited to pregnant
women and children [6,7]. In South Africa, ART is available to
only 22%–36% of those reported to be in need [8]. In settings
confronted with numerous new recommendations, not all of which
are immediately feasible, the relevant policy question is: What to do
first? Should countries begin by replacing stavudine with tenofovir
or by making CD4 count monitoring universally available? To
assist policy makers in this prioritization process, we use a model-
based analysis with data from South Africa to project the clinical
and economic outcomes of alternative stepwise implementation
scenarios toward the 2010 WHO ART guidelines.
Methods
Analytic Overview
The Cost Effectiveness of AIDS Complications (CEPAC)–
International model is a Monte Carlo simulation model of the
natural history and treatment of HIV disease (see Text S1 for
model details) [9–11]. We populate the model with South African
clinical and resource utilization data to project survival and costs
under alternative guideline prioritization scenarios. We use a ‘‘no
ART’’ scenario for comparison and assume that baseline care
(designated the ‘‘reference strategy’’) is a one-line stavudine-
containing regimen, initiated at WHO stage III or IV disease,
without CD4 count monitoring capacity. We then examine every
feasible sequence of the following implementation elements: (1)
widespread CD4 count monitoring capacity, allowing for ART
initiation at CD4,200 cells/ml (and biannual monitoring), (2)
earlier ART initiation, at CD4,350 cells/ml (assumes CD4 count
availability), (3) an available second-line ART regimen upon first-
line failure, and (4) replacement of stavudine with tenofovir in the
first-line regimen. To refer to these strategies, we use the
following nomenclature: nucleoside analog in first line/ART
initiation criterion/number of regimens [e.g., stavudine/,200/
ml/two-lines]). The combined implementation elements result in
twelve possible strategies, in addition to no ART (Figures 1 and
S1). We examine the short- and long-term survival benefits and
cost-effectiveness of each stepwise, incremental policy change
from the reference strategy to full 2010 guideline implementation.
We also evaluate the cost and survival impact of imposing an
additional ‘‘equity’’ constraint—i.e., that all members of the
cohort at any given time are provided the same treatment
program. Finally, we use sensitivity analyses to examine the
efficacy and cost input parameters necessary to change the
conclusions.
When reporting clinical outcomes alone (per-person life
expectancy), we provide undiscounted results. When clinical and
economic results are used to create cost-effectiveness ratios, we
adhere to established convention in discounting both at 3% per
annum [12]; cost-effectiveness ratios are reported in US dollars
per year of life saved (dollars/YLS) (See Text S1 for details). We
conduct an ‘‘incremental’’ assessment of economic costs and
health benefits, as recommended by the US Panel on Cost-
Effectiveness in Health and Medicine [12]. Cost and health
outcomes are estimated for all 12 strategies (as well as no ART).
These are then ranked in order of increasing cost. After
eliminating all ‘‘dominated’’ strategies (i.e., strategies that both
cost more and confer fewer benefits than any combination of other
strategies), we compute the ratio of incremental costs to
incremental benefits for each strategy, comparing it to its next-
least-costly, non-dominated alternative [12].
Costs are converted to 2008 US dollars using the South African
gross domestic product deflators and the 2008 mean exchange rate
between the South African rand and the US dollar (8.23 rand=US$1)
[13,14]. Guided by the recommendations of the WHO Commission
on Macroeconomics and Health, we consider interventions to be cost-
effective in a given country if their cost-effectiveness ratio is less than 3
times the national per capita gross domestic product (South African
2008 gross domestic product =US$5,700) [14].
The CEPAC-International Model
The CEPAC-International model simulates the progression of
disease in a hypothetical cohort of patients infected with HIV as a
sequence of monthly transitions between health states. Health states
are defined to be clinically and economically representative of the
disease courseand arestratifiedbycurrentCD4count,currentHIV
RNA level, and history of opportunistic disease. A graphical
representation of a patient trace in South Africa is presented in
Figure S2, illustrating CD4 cell count, HIV RNA, and clinical
events, including tuberculosis, over a hypothetical patient’s lifetime.
We are careful to distinguish in the model ‘‘actual’’ CD4 cell count
and HIV RNA—i.e., the underlying immunologic and virologic
state,regardlessofwhethertheyaremeasuredbyalaboratorytest—
from ‘‘observed’’ CD4 cell count and HIV RNA—that which is
measured by a test and upon which clinical decisions can be made.
Actual CD4 cell count determines the frequency of opportunistic
diseases, while ART influences actual HIV RNA levels and CD4
cell counts. Health states therefore reflect the underlying disease
process, and clinical decisions (ART initiation or switch) are based
on observed factors such as presentation with an opportunistic
disease, or CD4 count, if monitoring is available. Reflecting
standards of care in most sub-Saharan African nations, HIV RNA
monitoring is assumed to be unavailable [1]. Patients are followed
from entry into HIV care through death.
In strategies without available CD4 monitoring, decisions
regarding ART initiation and switching are made based upon
observation of any of the following severe opportunistic diseases
representative of WHO stage III/IV disease: severe bacterial
infection, severe fungal infection, tuberculosis, toxoplasmosis,
nontuberculous mycobacteriosis, Pneumocystis jiroveci pneumonia,
or other WHO stage IV defining diseases. Two mild oppor-
tunistic diseases (fungal and other) result in resource utilization
but no changes in the ART decision-making process. Patients
die in the model from an acute event (e.g., an opportunistic
disease or a drug-related toxicity), from chronic HIV disease, or
at South African age- and sex-adjusted background mortality
rates [15].
The frequency of clinical and laboratory assessments in the
model is user-defined. For this analysis, we have chosen clinical
assessments to occur every 3 mo; in strategies where CD4 counts
are available, they are modeled as being performed biannually.
Prioritizing HIV Care
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defined CD4 count threshold or the development of WHO III/IV
disease (i.e., severe opportunistic disease). Effective ART in the
model results in actual virologic suppression (independent of
gender), a CD4 count increase, and a CD4-independent reduction
in risk of opportunistic diseases and chronic AIDS death [16–19].
Because HIV RNA monitoring is unavailable, virologic failure on
an antiretroviral regimen is itself not detected. However, the
impact of virologic failure is ultimately observed when it manifests
with immunologic dysfunction through either a documented
opportunistic disease or a CD4 decline that is revealed by
laboratory testing. Six months after ART initiation, observed
treatment failure is defined as meeting any one of the following
three criteria: the development of a severe opportunistic disease,
observation of a 50% decline from peak on-treatment CD4 count,
or observation of two consecutive CD4 counts below 100 cells/ml
[1]. Upon observed treatment failure, ART is switched if a
subsequent regimen is available or, if not, the failed regimen is
continued until death to maintain its modest decreases in the rates
of opportunistic disease and death [17,18]. For the purposes of this
analysis, we assume no treatment interruptions.
Stavudine- or tenofovir-related toxicity occurs with a one-time
probability, distributed over time since drug initiation. Depending
on the nature of the toxicity, toxicity results in a one-time cost
and/or a duration of costs spanning the time of increased need for
care. Certain types of toxicity—including lactic acidosis, lipody-
stropy, neuropathy, and nephrotoxicity—also result in a single
drug switch to zidovudine.
Evaluating Uncertainty
To converge on stable model output, we run a simulated cohort
of 1 million patients infected with HIV. Because the cohort size
can be varied in the simulation—i.e., we might also simulate 2
million or 5 million patients—95% confidence intervals and
standard deviations (SDs) do not adequately capture uncertainty in
simulation modeling. Instead, we adhere to the guidance of the US
Panel on Cost-Effectiveness in Health and Medicine for reporting
uncertainty in deterministic methods [12]. We use univariate
sensitivity analysis to examine the impact of variation in individual
input parameters. Having identified those variables that exert the
greatest influence on our conclusions, we then turn to multivariate
sensitivity analyses to examine the impact of simultaneous
variation in multiple parameters. This approach results in a large
variety of univariate and multivariate sensitivity analyses. We
report those instances in which variation of an underlying
parameter value has material impact on the findings and
conclusions. A more comprehensive description of relevant
sensitivity analyses is provided in Texts S2 and S3.
Figure 1. Clinical and policy decisions yield 12 implementation strategies. Clinical and policy decisions result in 12 possible implementation
strategies. These strategies are listed in Text S1. Squares represent decision points. The reference strategy is bolded. d4t, stavudine; TDF, tenofovir.
doi:10.1371/journal.pmed.1000382.g001
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Data sources for individual input parameters are referenced in
Table 1 and in Text S1.
Cohort characteristics. We define an ART-naı ¨ve cohort of
patients with HIV in South Africa, with mean age 32.8 y [20]. We
intentionally choose an initial cohort with a relatively high mean
CD4 cell count of 375 cells/ml (SD, 25 cells/ml). A cohort with a
lower mean CD4 cell count would not clearly demonstrate the
benefits of an ART initiation threshold of CD4,350 cells/ml, as
illustrated in sensitivity analyses (Text S2). Over 40% of the cohort
has HIV RNA.100,000 copies/ml (Table 1) [21]. In the model,
this ART-naı ¨ve cohort is then subject to the policies of ART
initiation and drug availability as indicated by each of the 12
strategies. In the absence of ART, the model tracks the patients’
natural history of disease for use in comparing the incremental
clinical benefits and costs. Figure S3 illustrates the internal
validation of South African data used to derive critical model input
parameters such as monthly mortality and opportunistic disease
incidence rates, stratified by CD4 count.
Opportunistic disease prophylaxis and ART efficacy. All
patients at model entry are provided co-trimoxazole prophylaxis,
conferring protection against mild and severe bacterial infections,
P. jiroveci ¸ and toxoplasmosis [22,23]. We assume a non-nucleoside
reverse transcriptase inhibitor–based ART regimen that includes
stavudine. This regimen results in a 24-wk virologic suppression
rate of 75% with a mean 48-wk CD4 count rise of 136 cells/ml
among those with suppression [19]. The monthly probability of
virologic failure after 24 wk is 0.02. When stavudine is replaced
with tenofovir in first-line regimens, in the absence of reliable
efficacy data for a tenofovir-based regimen in resource-limited
settings, we use a virologic suppression rate of 85% at 24 wk, as
reported in clinical trials [24,25]. Despite the improved rates of
virologic suppression, we want to maintain conservative
assumptions with regard to CD4 benefit among those
suppressed, so we use the same benefit (136 cells/ml) as that used
for the stavudine-based regimen [19]. From these studies, the
monthly probability of failure of tenofovir-based ART after 24 wk
is 0.01 [24,25].
When second-line ART is available, it is a lopinavir/ritonavir-
based regimen with a 24-wk suppressive efficacy of 78%, a
resultant CD4 count increase of 151 cells/ml, and a 0.03 monthly
probability of virologic failure after 24 wk [16]. In sensitivity
analyses, we examine the impact of improved efficacy of first-line
ART associated with the use of tenofovir and the impact of
alternative second-line ART efficacies (Text S3).
Costs. We consider HIV-associated direct medical costs,
including inpatient days, outpatient visits, medication costs, and
laboratory tests, when available (Table 1). Direct non-medical
costs and indirect costs are excluded. Costs attributable to
inpatient hospitalization resulting from an opportunistic infection
are calculated as the mean cost of each inpatient day multiplied by
the mean length of stay for any given opportunistic disease.
Outpatient care costs include the mean cost of each visit, inclusive
of standard laboratory tests and procedures. Routine care costs are
stratified by CD4 cell count to account for the increased frequency
of visits that may be attributable to lower CD4 cell counts
(Table 1). The stavudine-based first-line regimen costs US$100 per
person-year (stavudine component = US$36), and the tenofovir-
based regimen costs US$204 per person-year (tenofovir
component = US$135) [26]; all other first-line regimen costs
are identical. Second-line ART regimens, when available, cost
US$669 per person-year [26]; CD4 count tests cost US$25 each
[27,28]. Tenofovir, second-line ART, and CD4 monitoring costs
are each varied in sensitivity analyses.
Results
Prioritization by Survival Benefits (Undiscounted)
An untreated HIV-infected South African cohort starting with a
mean CD4 count of 375 cells/ml (SD, 25 cells/ml) has a mean
undiscounted life expectancy of 47.9 mo. A single-line stavudine-
based ART regimen, initiated on development of WHO stage III/
IV disease (‘‘reference strategy’’; stavudine/WHO/one-line) in-
creases life expectancy to 99.0 mo. Table 2 provides the projected
5-ysurvivalandlife expectanciesofalternative stepwiseprogressions
toward the 2010 WHO recommendations. Compared to stavu-
dine/WHO/one-line (step 1), 5-y survival is largest (87% survival)
with the addition of CD4 count availability and ART initiation at
CD4,350 cells/ml (stavudine/,350/ml/one-line). In this initial
step, tenofovir/WHO/one-line (66%), stavudine/,200/ml/one-
line (80%), or stavudine/WHO/two-lines (66%) each yield lower
projected short-term survival. Considering each of the guideline
components, stavudine/,350/ml/one-line also produces the great-
est anticipated life expectancy increase, D25.3 mo. With stavudine/
,350/ml/one-line (step 2), adding a second-line regimen results in
the next largest life expectancy increase (stavudine/,350/ml/two-
lines, D53.3 mo). The final step replaces stavudine with tenofovir
(tenofovir/,350/ml/two-lines, D16.0 mo, step 3), resulting in a
comprehensive strategyconcordantwiththe 2010WHOguidelines,
a 5-y survival of 91%, and a projected life expectancy of 193.6 mo
(Table 2).
Model-generated survival curves are provided for no ART, the
reference strategy, and the three steps in Table 2, which act
stepwise to maximize life expectancy (Figure 2). Marked
differences in early survival are attributable to earlier ART
initiation thresholds; differences in survival later in the disease
course are associated with second-line ART availability.
Prioritization by Cost-Effectiveness
Incremental cost-effectiveness analysis (Table 3) reveals three
non-dominated strategies (i.e., strategies that attain a given survival
level by the least costly means): (1) stavudine/,350/ml/one-line
(US$610/YLS), (2) tenofovir/,350/ml/one-line (US$1,140/YLS),
and (3) tenofovir/,350/ml/two-lines (US$2,370/YLS). All other
strategies are ‘‘dominated’’—i.e., they are more expensive and
confer less survival benefit than some other combination of
strategies. Figure 3 (upper panel) maps the 13 strategies on a
discounted cost and life expectancy plane. The line connecting the
non-dominated strategies designates the ‘‘efficient frontier,’’ which
representsboththeleastexpensivewaytoattaina givensurvivaland
the maximum achievable survival for any given cost [12].
Thus, a country with a current stavudine/WHO/one-line
policy (Figure 3, lower panel) could switch to a tenofovir/,350/
ml/one-line policy (open arrow) and thereby simultaneously
decrease projected per-person lifetime costs and improve survival.
Similarly, a country with a stavudine/,200/ml/one-line policy
could decrease per-person costs and also improve outcomes by
changing to a stavudine/,350/ml/one-line policy (solid arrow-
head). Countries with a stavudine/,200/ml/two-lines policy
would require increased per-person expenditures to achieve the
survival benefits associated with tenofovir/,350/ml/two-lines, as
suggested in the revised WHO guidelines (dotted arrow).
Evaluating the Cost of Equity
Of the three efficient programs (Table 3; Figure 3), tenofovir/
,350/ml/one-line has a projected per-person lifetime cost of
US$6,870, and tenofovir/,350/ml/two-lines has a projected
lifetime cost of US$12,820. An HIV program budget that allows
for a per-person cost between US$6,870 and US$12,820 might be
Prioritizing HIV Care
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Variable Estimate Reference
Initial cohort characteristics
Age, mean years 6 SD 32.869.2 [20]
Male (%) 54.6 [20]
Distribution of initial CD4, mean cells/ml (SD) 375 (25) Assumption
HIV RNA distribution (%) [21]
.100,000 copies/ml 42.5
30,001–100,000 copies/ml 28.3
10,001–30,000 copies/ml 17.9
3,001–10,000 copies/ml 7.8
501–3,000 copies/ml 2.3
,500 copies/ml 1.2
Natural history of disease
Mean monthly CD4 decline (cells/ml) by HIV RNA stratum (copies/ml) [35]
.30,000 6.4
10,001–30,000 5.4
3,001–10,000 4.6
501–3,000 3.7
Monthly risk of severe opportunistic infections (%)
a [20]
Bacterial 0.08–0.71
Fungal 0.02–2.22
Tuberculosis 0.21–1.96
Toxoplasmosis 0.00–0.06
Nontuberculosis mycobacteriosis 0.00–0.30
P. jiroveci pneumonia 0.00–0.12
Other severe opportunistic infections 0.25–2.57
Monthly risk of mild opportunistic diseases (%)
a [20]
Fungal 0.59–3.51
Other 2.51–3.10
Efficacy of co-trimoxazole (% reduction in probability of infection)
Severe bacteria 49.8 [22,23]
Mild fungal infections 246.4
b [22,23]
Toxoplasmosis 83.2 [22,23]
P. jiroveci pneumonia 97.3 [22,23]
Other WHO stage IV defining diseases 17.9 [22]
Efficacy of ART (range examined)
First line: stavudine-based regimen [19]
HIV RNA suppression 75% at 24 wk
CD4 count increase 136 cells/mla t4 8w k
Probability of later failure (monthly, after 24 wk) 0.02
c (0.01–0.02)
First line: tenofovir-based regimen
HIV RNA suppression 85% at 24 wk (85%–95%) [24]
CD4 count increase 136 cells/ml at 48 wk [19]
Probability of later failure (monthly, after 24 wk) 0.01
d (0.005–0.01) [24]
Second line: lopinavir/ritonavir-based regimen [16]
HIV RNA suppression 78% at 24 wk (40%–88%)
CD4 count increase 151 cells/mla t4 8w k
Probability of later failure (monthly, after 24 wk) 0.03
e (0.01–0.06)
Toxicity (one-time probability [%])
Stavudine-based regimen (range examined)
Severe lactic acidosis 1.7 (1.7–3.4) [36]
Prioritizing HIV Care
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proportionately divide the cohort between two of the programs
along the efficient frontier, so that part of the cohort receives
tenofovir/,350/ml/one-line and the rest receives tenofovir/
,350/ml/two-lines. An alternative would be to provide everyone
in the cohort a third program—one that lies below the efficient
frontier. The opportunity cost (e.g., the anticipated net loss in
discounted life expectancy associated with an alternative strategy
choice) of any non-efficient strategy may be quantified by
measuring its vertical distance from the efficient frontier. To
illustrate this opportunity cost, we take an arbitrary affordability
threshold of US$11,500 per person. In the example of a program
that can afford no more than US$11,500 per person (stavudine/
,200/ml/two-lines; Figure 3, lower panel), the opportunity cost of
uniformity in care (‘‘equity’’) is 14.5 mo per person of survival
(shown by the bracket in Figure 3, lower panel).
Sensitivity Analyses
Clinical parameters. In sensitivity analyses, we examine
changes in clinical input data required to alter the stepwise
Variable Estimate Reference
Lipodystrophy 1.3 (1.3–2.6) [36]
Neuropathy 2.6 (2.6–5.2) [36]
Tenofovir-based regimen (range examined)
Nephrotoxicity 1.6 (1.6–3.2) [37,38]
Anemia 0.4 (0.4–0.8) [24]
Discount rate 3% [12]
Costs (2008 US dollars) (range examined)
Co-trimoxazole prophylaxis (monthly) 1.03 [23]
Stavudine-based first-line ART (monthly) 8.33 [26]
Tenofovir-based first-line ART (monthly) 17.00 (10.00–17.00) [26]
Lopinavir/ritonavir second-line ART (monthly) 55.75 (8.36–55.75) [26]
Routine care (range by CD4, monthly)
a 9.99–131.23 [20,39,40]
Inpatient hospital care, per day 224.25 [39]
Outpatient hospital care, per visit 10.87 [39]
CD4 count test US$25 (25–75) [27,28,41]
‘‘Range examined’’ indicates that we examined both extreme and intermediate values within the specified ranges.
aRange indicated by CD4 count; details by CD4 strata are presented in the Text S1.
bThe percent monthly risk of mild fungal infections is increased by 46.4% in the presence of co-trimoxazole [22].
cProjected using published 24-wk data [19].
dEstimated from published 24- and 48-wk data [24].
eEstimated from published 24- and 48-wk data [16].
doi:10.1371/journal.pmed.1000382.t001
Table 1. Cont.
Table 2. Projected life expectancies associated with alternative choices in the stepwise progression toward full implementation of
the 2010 WHO HIV treatment guidelines.
Step
5-y
Survival (%)
Projected Life
Expectancy (Months)
D Projected Life
Expectancy (months)
a
Step 1: begin with stavudine/WHO/one-line (reference strategy) (four options) 65 99.0 —
(1) Switch from stavudine to tenofovir, or 66 112.9 13.9
(2) Add CD4 monitoring capacity, initiate ART at CD4,200 cells/ml, or 80 115.6 16.6
(3) Add second-line ART regimen, or 66 121.4 22.4
(4) Add CD4 monitoring capacity, initiate ART at CD4,350 cells/ml 87 124.3 25.3
Step 2: begin with stavudine/,350/ml/one-line (two options) 87 124.3 —
(1) Switch from stavudine to tenofovir, or 89 144.8 20.5
(2) Add second-line ART regimen 91 177.6 53.3
Step 3: begin with stavudine/,350/ml/two-lines (one remaining option) 91 177.6 —
(1) Switch from stavudine to tenofovir 91 193.6 16.0
We use the following nomenclature to define the strategies: nucleoside analog used in first line/ART initiation criterion/number of available regimens. All strategies with
initiation criteria indicated by a CD4 count threshold assume availability of CD4 count monitoring. For each step, the option that maximizes survival is shown in bold.
aChange relative to the program selected in the previous step.
doi:10.1371/journal.pmed.1000382.t002
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CD4 count of the cohort (to 250 cells/ml) show decreased clinical
benefits to earlier ART initiation but no substantial changes in
cost-effectiveness. When the mean CD4 count of the cohort is less
than 100 cells/ml, the benefits of a policy change to earlier ART
initiation are largely irrelevant (Text S2). This is because the
majority of the cohort is already ART-eligible regardless of the
initiation criterion (WHO stage III/IV disease, CD4,200 cells/
ml, or CD4,350 cells/ml). Although CD4 monitoring still
improves cohort survival compared to clinically based ART
initiation, in populations with mean CD4 counts far below the
policy-relevant ART initiation criteria, the addition of a second-
line regimen becomes the most clinically beneficial intervention.
For the anticipated life expectancy benefits of tenofovir/WHO/
one-line to exceed those expected with stavudine/,350/ml/one-
line, replacement of stavudine with tenofovir would have to
increase the 24-wk suppressive efficacy from 85% to 95% and
simultaneously decrease the monthly probability of later virologic
failure by 50% (from 0.01 to 0.005) (Text S3) [24]. Second-line
ART maintains its position in the stepwise order (step 2) as long as
its 24-wk viral suppression rate remains between 40% and 88%,
even with a 3-fold increase in the rate of late failure when efficacy
decreased to 40% (Text S3). Increasing stavudine toxicity by 2-fold
alters life expectancy estimates by less than 1 mo and does not
change the recommended stepwise additions (Text S3). Similarly,
changes in the gender distribution of the cohort have little impact
on the results (Text S3).
Cost parameters. Holding efficacy constant, results are very
sensitive to the price of tenofovir; a decrease in the cost of tenofovir
from US$135 to US$51 per person per year would make tenofovir
both more effective and less costly than stavudine. Results are less
sensitive to the costs of second-line regimens (15% of base case)
and CD4 monitoring (three times base case), neither of which
produced meaningful changes in cost-effectiveness results (Text
S2). In two-way sensitivity analyses, where the cost of tenofovir is
decreased and its efficacy increased, tenofovir/,350/ml/one-line
dominates stavudine/,350/ml/one-line when the tenofovir
regimen costs are US$153 annually (75% of the base case) and
its 24-wk suppressive efficacy is 90% (5% increase from the base
case).
Additional sensitivity analyses. Further sensitivity analyses
are detailed in the Texts S2 and S3. In Text S2, we present the 1-
through 5-y survival rates for all 12 strategies examined, as well as
the survival curves of the stepwise strategies selected on a 5-y,
rather than a 10-y, horizon (Figure S4). Text S2 also provides the
details of analyses under conditions of alternative mean CD4
counts for the cohort and alternative costs of both second-line
regimens and CD4 monitoring. Further analyses (Text S3) offer
Figure 2. Model-projected survival curves. Model-projected survival curves (undiscounted) of the reference strategy (stavudine/WHO/one-line)
and the three strategies projected to maximize life expectancy in stepwise progression toward the 2010 WHO guidelines (see Results and Table 2 for
details). Curves highlighting outcomes over the next 5 y are provided in Figure S4. The 20-y horizon is presented here, not to imply that HIV
treatment will remain unchanged over this time horizon, but rather to demonstrate when different interventions will have meaningful survival
impacts. Median survival increases from 90 mo with stavudine/WHO/one-line (reference strategy) to 121 mo with the addition of CD4 monitoring
and ART initiation at CD4,350 cells/ml (stavudine/,350/ml/one-line, step 1) to 177 mo with the addition of a second-line ART regimen (stavudine/
,350/ml/two-lines, step 2). A subsequent switch from stavudine to tenofovir results in a comparatively modest survival advantage, with a median
survival increase to 196 mo (tenofovir/,350/ml/two-lines, step 3). The survival curve of step 3 represents what might be expected when all the 2010
WHO treatment guidelines are fully implemented.
doi:10.1371/journal.pmed.1000382.g002
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distributions, ART initiation criteria, first- and second-line ART
efficacies, stavudine-related toxicities, and costs. Within plausible
ranges, these sensitivity analyses, other than those reported above,
had little impact on clinical- or policy-relevant results.
Discussion
The new 2010 WHO ART guidelines aim to promote public
health interventions that ‘‘secure the greatest likelihood of survival
and quality of life for the greatest number’’ of individuals with
HIV. The reported guiding principles in the revision process
include: (1) do no harm, (2) ensure access and equity, (3) promote
quality and efficiency, and (4) ensure sustainability. Motivated by
these tenets, the new guidelines recommend a single CD4-based
ART initiation criterion for all populations, a switch from
stavudine to tenofovir, and universally available second-line
regimens [2]. We find that in settings where immediate
implementation of all of the new WHO treatment guidelines is
currently not feasible, ART initiation at CD4,350 cells/ml
provides the greatest short- and long-term survival advantage
and is very cost-effective. In countries that are already initiating
stavudine at CD4,350 cells/ml and have access to CD4
monitoring, switching from stavudine to tenofovir increases
survival and is also cost-effective. Access to second-line ART
provides more clinical benefit than access to tenofovir but at
substantially greater costs.
The additional outlays implied by the new guidelines stand in
stark contrast to the resource-constrained reality encountered on
the ground. Many countries are still striving to meet goals set by
the now-superseded 2006 guidelines. The WHO estimates the
current ART coverage rate across low- and middle-income
countries to be 42% [5,29]. Meanwhile, the new guidelines
recommend access to CD4 count monitoring, call for treatment of
almost double the 3–5 million people already requiring treatment
based on the previous guidelines [30], and suggest replacement of
the most widely used antiretroviral drug with one that costs nearly
US$100 per patient-year more [26]. In most resource-limited
settings, the relevant policy questions are: What is feasible now? and
What to do first?
B a s e do np r o j e c t e ds h o r t -a n dl o n g - t e r ms u r v i v a la n dc o s t -
effectiveness results, we identify three critical messages. First,
countries with very limited resources and still only one line of ART
available should focus first on access to CD4 count monitoring and
ART initiation at CD4,350 cells/ml. These should be implemented
before switching from stavudine to tenofovir and prior to providing
second-line ART. Although advising to use stavudine in the first-line
regimen—with its inherent toxicities—may be seen as conflicting
withtheprimaryWHOprinciple‘‘first,donoharm,’’theswitchfrom
stavudine to tenofovir is the recommendation that provides the least
overall increase in survival, according to the results presented here.
Initiating stavudine-based ART at CD4,350 cells/ml, compared
with clinically based ART initiation, provides immediate and
substantial short-term survival benefits, yields the greatest life
expectancy compared to other guideline components, and is cost-
effective by international standards. In cases where most patients
present to care with CD4 counts far below the ART initiation
threshold (e.g., CD4,100 cells/ml), a policy of earlier ART initiation
is neutral at worst—both in terms of cost and clinical outcomes—as it
serves only to increase life expectancy among patients with less
advanced disease.
Second, countries with currently one line of ART available but
more resources should ensure access to CD4 count monitoring
with ART initiation at CD4,350 cells/ml and then switch from
stavudine to tenofovir, before making second-line ART available.
Indeed, some countries have already responded to the 2010 WHO
guidelines and have made plans to phase out stavudine [31].
Reductions in the price of tenofovir could resolve the ongoing
debate surrounding the role for stavudine in resource-limited
settings. At an annual cost of US$51, tenofovir would be both less
costly and more effective than stavudine.
Table 3. Life expectancy, costs, and incremental cost-effectiveness ratios of the 12 possible stepwise combinations (and no ART)
from the reference strategy to full implementation of 2010 WHO HIV treatment guidelines.
Strategy
a Discounted Cost
Discounted Per-Person Life
Expectancy (Undiscounted) Months
Incremental Cost-
Effectiveness Ratio (US$/YLS)
No ART 2,540 44.9 (47.9)
Stavudine/,350/ml/one-line (step 1) 5,550 104.3 (124.3) 610
Stavudine/,200/ml/one-line 5,740 97.3 (115.6) Dominated
b
Tenofovir/,350/ml/one-line 6,870 118.3 (144.8) 1,140
Tenofovir/,200/ml/one-line 6,930 109.9 (133.9) Dominated
b
Stavudine/WHO/one-line (reference strategy) 7,440 84.5 (99.0) Dominated
b
Tenofovir/WHO/one-line 8,400 93.9 (112.9) Dominated
b
Stavudine/WHO/two-lines 10,140 98.8 (121.4) Dominated
b
Tenofovir/WHO/two-lines 10,640 105.0 (131.2) Dominated
b
Stavudine/,200/ml/two-lines 11,460 127.0 (161.3) Dominated
c
Tenofovir/,200/ml/two-lines 11,930 135.3 (175.5) Dominated
c
Stavudine/,350/ml/two-lines (step 2) 12,270 138.7 (177.6) Dominated
c
Tenofovir/,350/ml/two-lines (step 3) 12,820 148.4 (193.6) 2,370
The reference strategy and the strategies selected in the stepwise progression in Table 2 are shown in bold.
aWe use the following nomenclature to define the strategies: nucleoside analog used in first line/ART initiation criterion/number of available regimens. All strategies
with initiation criteria indicated by a CD4 count threshold assume availability of CD4 count monitoring; WHO indicates WHO stage III/IV disease.
bStrongly dominated (more expensive but confer less clinical benefit than some other strategy) [12].
cWeakly dominated (more expensive but confer less clinical benefit than some combination of other strategies) [12].
doi:10.1371/journal.pmed.1000382.t003
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PLoS Medicine | www.plosmedicine.org 8 December 2010 | Volume 7 | Issue 12 | e1000382Figure 3. Clinical and economic outcomes of each of the scale-up interventions. The clinical and economic outcomes of all combinations of
scale-up interventions are examined. The efficient frontier (marked by the line) connects the non-dominated strategies in the cost-effectiveness
plane. Strategies below and to the right of the efficient frontier are those that are either strongly or weakly dominated by other options (see
Methods). As illustrated in the upper panel, strategies based on clinical criteria (WHO stage III/IV) alone fall far below the efficient frontier (lower right
oval), indicating their relatively high cost for the comparative benefit gained. Strategies in the upper left oval are those representing CD4 monitoring
and one line of ART. Strategies incorporating a second-line regimen (upper right oval) all confer large survival benefits but at increased costs. The
lower panel examines potential country situations. For instance, a country with a current stavudine/WHO/one-line policy could switch to a tenofovir/
,350/ml/one-line policy (open arrow) and both decrease projected per-person lifetime costs and improve survival. A country with a stavudine/,200/
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line ART, it is neither effective nor cost-effective to maintain
stavudine in first-line regimens. Second-line ART may offer
additional efficiencies by decreasing the prevalence of resistant
virus and leaving future drug regimen options available.
Once countries have the capacity to provide early ART
initiation, tenofovir, and second-line regimens, there will be
additional clinical and policy questions. Policy makers will be
addressing what to do upon second-line failure; optimal third-line
regimens will be in question. Expanded ART regimen availability
leads to clinical need for timely ART switches and forces the issue
of HIV RNA laboratory availability. Finally, timely ART initiation
is currently limited by late presentation to care [32,33].
Concurrent with scaling up to achieve the 2010 WHO ART
guidelines, there should be a concerted effort to achieve the 2007
WHO HIV screening guidelines [34]; without earlier case
detection, a policy of ART initiation at CD4,350 cells/ml will
never be effectively realized.
It is important to highlight that full and immediate implemen-
tation of the comprehensive set of new guidelines is cost-effective
by South African standards. But, while it is helpful to critically
examine the survival and economic efficiency of alternative
programmatic choices, ‘‘cost-effective’’ does not mean ‘‘afford-
able.’’ In the setting of clear budget constraints, the question of
affordability may conflict with the political imperative that all
persons receive the same care package. In this case, prioritization
of equity over efficiency decreases mean life expectancy—
sometimes by more than 1 y per person—for the same healthcare
expenditure (Figure 3, lower panel).
This analysis has several limitations. We report results from a
cohort of HIV-infected individuals initiating ART. Although we
believe the overall results would be consistent, this analysis does
not specifically address ART programs with patients already in
alternative stages of care, including some on first-line regimens,
some on second-line regimens, and some who have previously
accumulated drug-related toxicities. Such diversity within a cohort
would require more individualized analyses. Additionally, a full
budget impact analysis would be required to examine the number
of patients in need of care, and to project the implications of each
component of the WHO recommendation on program budgets
over alternative time horizons.
Despite its limitations, this analysis represents the only
systematic, scientific effort we are aware of that marshals the
evidence base in support of implementing the WHO guidelines.
The most unfortunate outcome upon release of the revised WHO
guidelines would be either their complete dismissal on cost
grounds alone, or the execution of more expensive—though easier
to implement—interventions that offer less overall health benefit
than other interventions.
In cases where the simultaneous implementation of all
components of the 2010 WHO ART guidelines is beyond the
reach of programs or countries, important prioritization questions
emerge. This analysis suggests that CD4 count monitoring and
ART initiation at CD4,350 cells/ml are the critical initial
priorities. Replacing stavudine with tenofovir would further
increase survival and would also be cost-effective. Adding a
second-line ART regimen would provide large survival benefits,
but with substantial increases in the necessary budgets.
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Background. Since 1981, acquired immunodeficiency
syndrome (AIDS) has killed more than 25 million people,
and about 33 million people (30 million of them in low- and
middle-income countries) are now infected with the human
immunodeficiency virus (HIV), which causes AIDS. HIV
destroys immune system cells (including CD4 cells, a type
of lymphocyte), leaving infected individuals susceptible to
other infections (so-called opportunistic infections). Early in
the AIDS epidemic, most people with HIV died within 10
years of infection. Then, in 1996, highly active antiretroviral
therapy (ART)—a combination of several powerful
antiretroviral drugs—was developed. Now, in resource-rich
countries, clinicians care for people with HIV by prescribing
ART regimens tailored to each individual’s needs. They also
regularly measure the amount of virus in their patients’
blood, test for antiretroviral-resistant viruses, and monitor
the health of their patients’ immune systems through regular
CD4 cell counts. As a result, the life expectancy of patients
with HIV in developed countries has dramatically improved.
Why Was This Study Done? Initially, resource-limited
countries could not afford to provide ART for their
populations, and the life expectancy of HIV-positive people
remained low. Now, through the concerted efforts of
governments, the World Health Organization (WHO), and
other international agencies, more than a third of the people
in low- and middle-income countries who need ART are
receiving it. However, many without access are still in need
of ART, and ART programs in developing countries follow a
public-health approach rather than an individualized
approach. That is, drug regimens, clinical decision-making,
and disease monitoring are all standardized and follow
recommendations in the 2006 WHO ART guidelines. This year
(2010), these guidelines were revised. The guidelines now
recommend the following: earlier ART initiation—when the
CD4 count falls below 350/ml of blood, instead of below 200/
ml as in the 2006 guidelines; the provision of sequential ART
regimens instead of a single regimen; and the replacement
of the antiretroviral drug stavudine with tenofovir, a less
toxic but more expensive drug, in first-line ART regimens.
However, many resource-limited countries are still struggling
to implement the 2006 guidelines, so which of these new
recommendations should be prioritized? Here, the
researchers use a mathematical model to address this
question.
What Did the Researchers Do and Find? The Cost
Effectiveness of AIDS Complications (CEPAC)–International
model simulates the natural history and treatment of HIV
disease. The researchers entered South African clinical and cost
data for HIV treatment into this model and then used it to
project survival and costs in a hypothetical group of South
African HIV-positive patients under alternative guideline
prioritization scenarios. The reference strategy for the
simulations (denoted as ‘‘stavudine/WHO/one-line’’) assumed
that patients (with a mean CD4 count of 375/ml) began a single
stavudine-based ART regimen when they developed WHO
stage III/IV HIV disease (i.e., when patients develop multiple
opportunistic infections such as tuberculosis and pneumonia).
When the new guideline recommendations were considered
separately, ART initiation at CD4,350/ml( s t a v u d i n e / ,350/ml/
one-line) maximized five-year survival. Stepwise adjustment
from the reference strategy (which had a life expectancy 99.0
months) through strategies of stavudine/,350/ml/one-line (a
projected life expectancy of 124.3 months), stavudine/,350/ml/
two-lines (177.6 months), and tenofovir/,350/ml/two-lines
(193.6 months) produced the greatest improvements in life
expectancy. Finally, strategies of stavudine/,350/ml/one-line,
tenofovir/,350/ml/one-line, and tenofovir/,350ml/two-lines
produced incremental cost-effectiveness ratios of US$610,
US$1,140, and US$2,370 per year of life saved, respectively.
What Do These Findings Mean? As with all mathematical
models, the accuracy of these findings are dependent on the
assumptions included in the model and on the data
populating it. Nevertheless, these findings suggest that,
where resources are limited and immediate implementation
of all the new WHO recommendations is impossible, ART
initiation at a CD4 count of less than 350/ml would provide
the greatest survival advantage and would be very cost-
effective. In countries that are already initiating ART at this
threshold and that have access to CD4 monitoring, a switch
from stavudine to tenofovir would further increase survival
and would also be cost-effective. Finally, although access to
a second-line ART regimen would provide more clinical
benefits than access to tenofovir, the cost of this change in
strategy would be substantially greater. Importantly, these
findings should help policy makers adjust their ART program
strategies to maximize their clinical benefits and cost
effectiveness.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000382.
N Information is available from the US National Institute of
Allergy and Infectious Diseases on HIV infection and AIDS
N HIV InSite has comprehensive information on all aspects of
HIV/AIDS
N Information is available from Avert, an international AIDS
charity, on many aspects of HIV/AIDS, including informa-
tion on HIV/AIDS in South Africa and on HIV/AIDS
treatment and care (in English and Spanish)
N WHO provides information about universal access to AIDS
treatment (in English, French, and Spanish); its 2010 ART
guidelines can be downloaded
N More information on the CEPAC model is available
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